论文部分内容阅读
目的研究以雷贝拉唑与加替沙星为基础的三联疗法根除幽门螺杆菌(Hp)的疗效、不良反应和药品的费用,以探讨临床更佳的根除Hp方案。方法选择符合条件的300例患者,随机分为A、B、C3组。A组:雷贝拉唑10mgbid,甲磺酸加替沙星200mgbid,甲硝唑100mgtid。B组:雷贝拉唑10mgbid,甲磺酸加替沙星200mgbid,阿莫西林500mgtid。C组(对照组):雷贝拉唑10mgbid,甲硝唑100mgtid,阿莫西林500mgtid。以上3组疗程均为2周。停药4周后复查胃镜或14C-UBT。结果A组、B组、C组Hp根除率分别为91%、92%及87%,3组相比,差异无统计学意义(P>0.05),未见发生严重不良反应者,A、B、C3组的治疗费用分别为200.13元、210.76元和149.60元。结论以雷贝拉唑与加替沙星为基础的三联疗法能有效、安全地根除Hp且能节省费用。
Objective To study the curative effect, side effects and drug cost of triple therapy with rabeprazole and gatifloxacin in the eradication of Helicobacter pylori (Hp) in order to explore a better clinical program of eradication of Hp. Methods 300 eligible patients were randomly divided into A, B and C3 groups. Group A: rabeprazole 10mgbid, gatifloxacin mesylate 200mgbid, metronidazole 100mgtid. Group B: rabeprazole 10mgbid, gatifloxacin mesylate 200mgbid, amoxicillin 500mgtid. Group C (control group): rabeprazole 10mgbid, metronidazole 100mgtid, amoxicillin 500mgtid. The above three groups of treatment are 2 weeks. Four weeks after discontinuation of gastroscopy or 14C-UBT. Results The Hp eradication rates in group A, group B and group C were 91%, 92% and 87% respectively. There was no significant difference between the three groups (P> 0.05). No serious adverse reactions were observed. A and B , C3 group treatment costs were 200.13 yuan, 210.76 yuan and 149.60 yuan. Conclusions Triple therapy with rabeprazole and gatifloxacin can effectively and safely eradicate Hp and save money.